Disposition of the selective alpha1A-adrenoceptor antagonist tamsulosin in humans: comparison with data from interspecies scaling
- PMID: 9344174
- DOI: 10.1021/js960303k
Disposition of the selective alpha1A-adrenoceptor antagonist tamsulosin in humans: comparison with data from interspecies scaling
Abstract
Tamsulosin-HCl is an alpha1A-adrenoceptor antagonist that is mainly eliminated by metabolism in animals and humans and is highly bound to alpha1-acid glycoprotein in blood plasma. The disposition of the compound (0.4 mg as modified-release granules in a capsule) was determined in male volunteers, using intravenous (iv) infusion of tamsulosin-HCl (0.125 mg over 4 h) as reference treatment for the assessment of absolute oral bioavailability. Disposition parameters of iv tamsulosin in humans was compared with data predicted from animal data by interspecies scaling techniques. Levels after iv dosing in humans showed a biexponential decline, with mean half-lives (+/-SD) of 1.2 +/- 0.6 and 6.8 +/- 3.5 h, respectively. The mean systemic clearance (+/-SD) was low (viz., 48 +/- 24 mL/min). The mean volume of distribution (+/-SD) was rather small (21 +/- 6 L), and was estimated at 16 +/- 4 L in the steady state. The mean absolute oral bioavailability (+/-SD) was approximated at 100 +/- 19%. Systemic clearance in humans was poorly predictable from a logarithmic clearance versus body weight relation of rat, rabbit, and dog data. The prediction improved dramatically (accuracy 213%) when scaling was done with systemic clearance values of unbound drug, and it improved further (accuracy 59%) with the product of unbound clearance and maximum life-span potential. Also, the prediction of volume of distribution improved dramatically (accuracy 81%) after correction for differences in extent of protein binding between species. The terminal disposition half-life of 7.0 h, as predicted after integrating maximum life-span potential and protein binding in scaling of clearance, was very close to the value of 6.8 h established experimentally in humans. The present results with tamsulosin underline the importance of correction for extent of protein binding in allometric scaling of clearance and distribution volume.
Similar articles
-
Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations.Clin Pharmacokinet. 2010 Mar;49(3):177-88. doi: 10.2165/11317580-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20170206 Review.
-
Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans.Drug Metab Dispos. 1998 Mar;26(3):240-5. Drug Metab Dispos. 1998. PMID: 9492387
-
Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics.Br J Clin Pharmacol. 1998 Jan;45(1):49-55. doi: 10.1046/j.1365-2125.1998.00636.x. Br J Clin Pharmacol. 1998. PMID: 9489594 Free PMC article. Clinical Trial.
-
In vivo measurement by [3H]Tamsulosin of alpha1 adrenoceptors in rat tissues in relation to the pharmacokinetics.J Pharmacol Exp Ther. 1999 Jun;289(3):1575-83. J Pharmacol Exp Ther. 1999. PMID: 10336555
-
Scaling basic toxicokinetic parameters from rat to man.Environ Health Perspect. 1996 Apr;104(4):400-7. doi: 10.1289/ehp.96104400. Environ Health Perspect. 1996. PMID: 8732950 Free PMC article. Review.
Cited by
-
Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations.Clin Pharmacokinet. 2010 Mar;49(3):177-88. doi: 10.2165/11317580-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20170206 Review.
-
Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder.Br J Clin Pharmacol. 2010 Jul;70(1):88-101. doi: 10.1111/j.1365-2125.2010.03662.x. Br J Clin Pharmacol. 2010. PMID: 20642551 Free PMC article. Clinical Trial.
-
Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations.Clin Pharmacokinet. 1999 Mar;36(3):211-31. doi: 10.2165/00003088-199936030-00003. Clin Pharmacokinet. 1999. PMID: 10223169 Review.
-
Population pharmacokinetics of tamsulosine in patients with benign prostatic hyperplasia.World J Urol. 2024 Jul 22;42(1):427. doi: 10.1007/s00345-024-05115-w. World J Urol. 2024. PMID: 39037497
-
Fractal volume of drug distribution: it scales proportionally to body mass.Pharm Res. 2001 Jul;18(7):1056-60. doi: 10.1023/a:1010965001162. Pharm Res. 2001. PMID: 11496945
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources